

CLAIMS

What is claimed is:

*Sub Q2*  
1 A gene delivery vehicle having been provided with at least a tissue tropism for dendritic cells wherein said tissue tropism for dendritic cells is provided by a viral capsid protein.

5 2. The gene delivery vehicle of claim 1 wherein said tissue tropism is provided by viral capsid that comprises protein fragments derived from at least two different viruses.

*a*  
3. The gene delivery vehicle of claim 2, wherein at least one of said at least two different viruses is an adenovirus.

*Sub Q3*  
4. The gene delivery vehicle of claim 3 wherein at least one of said at least two different viruses is an adenovirus of subgroup B.

5. The gene delivery vehicle of claim 2, wherein at least one of said protein fragments comprises a tissue tropism determining fragment of a fiber protein derived from a subgroup B adenovirus.

15 6. The gene delivery vehicle of claim 3, wherein at least one of said protein fragments comprises a tissue tropism determining fragment of a fiber protein derived from a subgroup B adenovirus.

*Subs C16*  
7. The gene delivery vehicle of claim 4, wherein said subgroup B adenovirus is adenovirus 16.

20 8. The gene delivery vehicle of claim 5, wherein said subgroup B adenovirus is adenovirus 16.

9. The gene delivery vehicle of claim 6, wherein said subgroup B adenovirus is adenovirus 16.

10. The gene delivery vehicle of claim 5, further comprising protein fragments derived from an adenovirus of subgroup C.

5 11. The gene delivery vehicle of claim 6, further comprising protein fragments derived from an adenovirus of subgroup C. *a*

12. The gene delivery vehicle of claim 7, further comprising protein fragments derived from an adenovirus of subgroup C.

13. The gene delivery vehicle of claim 1, comprising adenoviral nucleic acid, said adenoviral nucleic acid comprising at least one sequence encoding a fiber protein having at least a tissue tropism determining fragment of a subgroup B adenovirus fiber protein.

14. The gene delivery vehicle of claim 13, wherein said adenovirus nucleic acid is modified such that the capacity of said adenoviral nucleic acid to replicate in a target cell has been reduced or disabled.

15. The gene delivery vehicle of claim 13, wherein said adenoviral nucleic acid is modified such that the capacity of a host immune system to mount an immune response against adenovirus proteins encoded by said adenovirus nucleic acid has been reduced or disabled.

16. The gene delivery vehicle of claim 14, wherein said adenoviral nucleic acid is modified such that the capacity of a host immune system to mount an immune response against adenovirus proteins encoded by said adenovirus nucleic acid has been reduced or disabled.

17. The gene delivery vehicle of any one of claim 1, wherein said gene delivery vehicle

comprises a minimal adenovirus vector or an Ad/AAV chimaeric vector.

*Sub an* 18. The gene delivery vehicle of claim 1, further comprising at least one non-adenoviral nucleic acid.

5 19. An adenovirus capsid having a tissue tropism for dendritic cells wherein said adenovirus capsid comprises:

proteins from at least two different adenoviruses, and  
a tissue tropism determining fragment of a fiber protein derived from a subgroup B adenovirus.

10 20. A composition comprising a gene delivery vehicle having been provided with at least a tissue tropism for dendritic cells, said tissue tropism for dendritic cells being provided by a virus capsid, said virus capsid comprising protein fragments derived from at least two different viruses, wherein at least one of said at least two different viruses is an adenovirus of subgroup B.

15 21. The composition of claim 20 wherein the adenovirus of subgroup B is selected from the group of adenoviruses consisting of Ad16, Ad35, Ad11, and Ad51.

22. The gene delivery vehicle of claim 3 wherein the adenovirus is Ad40L.

*add 22*  
*add 22*  
*add 22*